Pricing Log in Create free account
Friday 6 November 2026 Export STAA’s income statement to Excel — free account

STAAR Surgical Company

STAA Healthcare Medical Instruments & Supplies

STAAR Surgical Company’s revenue for fiscal 2025 (year ended December 2025) was $239.4 million, down 23.7% from fiscal 2024.

Revenue
−12.0%
EPS
−38.9%
Free cash flow
+1,378.7%

Quarter to September 2026, against a year earlier

26.47 0.70 −2.58%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
84.4×
Dividend yield
—
F-score
2/9
Altman Z
6.44
Beneish M
−3.29
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 21.69
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — 2 — 1 — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 40.01%

Capital & Financial Ratios $m

Size
Market Cap 1,340.00
Revenue ttm 328.27
Net income ttm 0.53
Free cash flow ttm 17.85
Net debt Q (206.41)
Valuation
P/E 0.00
Forward P/E 84.40 (above 35: high)
Price / sales 4.08
Forward P/S Powerpack
Price / FCF 75.31
Price / book 3.56
Financial health
Current ratio Q 4.68 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 3.72
Growth
Revenue growth Q −11.95% (below 0%: shrinking)
Operating income growth Q −70.48% (below 0%: shrinking)
EPS, this year +133.50% (at or above 15%: strong)
EPS, next year A +73.55% (at or above 15%: strong)
Revenue, next year A +39.62% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +43.03% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.5×, against a ten-year median of 6.9×; over the ten years it ranged from 2.0× in 2025 to 37.1× in 2021.
P/S against its own 10 years 16.35%
10-year low 10-year high
P/B against its own 10 years 13.57%
10-year low 10-year high
EV/Sales against its own 10 years 15.73%
10-year low 10-year high
EV/FCF against its own 10 years 5.33%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 221 230 188 206
Receivables 95 78 50 87
Inventory 35 43 55 45
Other — — — —
365 368 312 353
2023 2024 2025 Q'26
Payables 14 17 12 14
ST’ Debt — — — —
Other 47 50 51 —
65 70 69 76

Compound Annual Growth %

10y 5y 3y
Sales 12.00% 7.93% (5.57%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 24.38% 11.78% 0.79%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.19 Actual 0.34

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.16 0.04 Miss by 0.12
Q1 FY26 0.13 0.38 Beat by 0.25
Q2 FY26 0.21 0.31 Beat by 0.10
Q3 FY26 0.19 0.34 Beat by 0.15
Q4 FY26 0.12 — Reports 2 March 2027

EPS $

Mar Jun Sep Dec Year
’26 0.10 0.16 0.11 — —
’25 (1.10) (0.34) 0.18 (0.37) (1.62)
’24 (0.07) 0.15 0.20 (0.69) (0.41)
’23 0.05 0.12 0.10 0.16 0.43
’22 0.19 0.26 0.21 0.12 0.78
’21 0.10 0.17 0.12 0.16 0.56
’20 0.00 (0.03) 0.08 0.07 0.12
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 94 94 83 — —
’25 43 44 95 58 239
’24 77 99 89 49 314
’23 74 92 80 76 322
’22 63 81 76 64 284
’21 51 62 58 59 230
’20 35 35 47 46 163
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) 20 27 — —
’25 (6) (27) 3 (4) (34)
’24 22 (10) 4 1 16
’23 (5) (6) (6) 32 15
’22 (5) 13 24 3 36
’21 7 6 22 8 44
’20 (8) 0 10 20 21
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (22) 19 26 — —
’25 (7) (29) 2 (6) (40)
’24 16 (17) (2) (5) (8)
’23 (8) (9) (15) 29 (4)
’22 (7) 8 18 (1) 18
’21 5 3 19 4 30
’20 (10) (2) 8 17 13
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 82 91 124 150 163 230 284 322 314 239 328 +12.6% 334 361 389 +17.6%
Gross margin, % 70.81 70.94 73.83 74.54 72.41 77.51 78.55 78.36 76.32 76.19 73.56 +5.4 pt
EBT (12) (2) 7 13 8 31 46 34 (9) (82) 6 +23.3%
EBT margin, % (15.10) (2.53) 5.36 8.67 5.06 13.58 16.02 10.45 (2.88) (34.36) 1.70 (19.3) pt
Net income (12) (2) 5 14 6 28 40 21 (20) (80) 1 +23.4%
Per share, $
Per share, $ Revenue 2.04 2.21 2.91 3.38 3.58 4.88 5.93 6.64 6.39 4.83 6.50 +10.0%
Earnings (0.30) (0.05) 0.12 0.32 0.13 0.58 0.81 0.44 (0.41) (1.62) 0.00 +20.6%
Cash flow 0.03 0.07 0.30 0.58 0.46 0.93 0.74 0.30 0.32 (0.69) 0.42 n/m
Capex (0.08) (0.03) (0.05) (0.23) (0.18) (0.29) (0.38) (0.37) (0.48) (0.12) (0.07) +4.4%
Free cash flow (0.05) 0.04 0.25 0.35 0.28 0.64 0.37 (0.07) (0.16) (0.81) 0.35 +35.2%
Book value 0.94 1.05 3.11 3.59 4.32 5.48 7.00 7.95 8.09 6.94 7.44 +24.9%
Shares, m 40 41 43 44 46 47 48 49 49 50 50 +2.3%
Valuation, ×
Valuation, × P/E 0.00 0.00 306.53 113.45 677.09 155.54 64.06 66.07 0.00 0.00 0.00 138.3
P/S 5.23 7.20 10.96 10.42 22.10 18.70 8.65 4.47 3.80 4.78 4.08 9.6
P/B 11.38 15.18 10.26 9.79 18.32 16.67 7.32 3.74 3.00 3.33 3.56 9.9
EV/Sales 5.08 7.00 10.13 9.62 21.17 17.84 7.90 3.79 3.07 4.13 3.54 9.0
EV/FCF (194.28) 350.84 119.32 92.54 277.63 135.97 128.28 (332.31) (124.20) (24.65) 65.45 42.9
Cash, $m
Cash, $m Operating cash flow 1 3 13 26 21 44 36 15 16 (34) 21 n/m
Capex (3) (1) (2) (10) (8) (14) (18) (18) (23) (6) (4) +6.9%
Free cash flow (2) 2 11 16 13 30 18 (4) (8) (40) 18 +38.4%
Balance, $m
Balance, $m Working capital 28 35 124 140 175 223 260 300 298 243 278 +26.9%
Net debt (13) (18) (103) (120) (152) (199) (211) (221) (230) (188) (206) +34.9%
Shareholders’ equity 38 43 132 160 197 259 336 386 397 344 376 +27.8%
Returns, %
Returns, % ROA (18.89) (3.21) 4.22 7.50 2.54 9.12 10.38 4.70 (4.05) (16.74) 0.11 +2.2 pt
ROIC (31.33) (9.10) 14.21 18.39 9.44 35.18 21.96 10.63 (4.72) (36.59) 0.26 (5.3) pt
ROE (31.61) (5.29) 5.67 9.61 3.31 12.07 13.34 5.91 (5.16) (21.70) 0.15 +9.9 pt
People
People Employees 336 353 475 550 575 806 964 1,115 1,211 957 — +12.3%
Revenue/emp, $m 0.25 0.26 0.26 0.27 0.28 0.29 0.30 0.29 0.26 0.25 — +0.2%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

STAAR Surgical Company vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
WRBY Warby Parker Inc. $3.2B 434× 208× +10.40% (above 0%: growing) −20.00% (below 0%: shrinking) −30.28% (below 0%: shrinking) 54.41% 1.45% Compare
ATRC AtriCure, Inc. $3.1B 199× 573× +15.03% (above 0%: growing) n/m −0.73% (below 0%: shrinking) 77.27% 2.82% Compare
XRAY DENTSPLY SIRONA Inc. $2.0B — (loss-making) 24.5× −7.52% (below 0%: shrinking) n/m −17.95% (below 0%: shrinking) 52.99% 4.43% Compare
LMAT LeMaitre Vascular, Inc. $1.9B 29.7× 28.2× +11.34% (above 0%: growing) −14.29% (below 0%: shrinking) −25.78% (below 0%: shrinking) 71.66% 26.03% Compare
KMTS Kestra Medical Technologies, Ltd. $1.7B — (loss-making) — (loss-making) +59.88% (above 0%: growing) n/m −17.75% (below 0%: shrinking) 56.50% (121.59%) Compare
AZTA Azenta, Inc. $1.6B — (loss-making) — (loss-making) +12.04% (above 0%: growing) n/m −134.69% (below 0%: shrinking) 44.89% (2.59%) Compare
STAA STAAR Surgical Company $1.3B — (loss-making) 84.4× −11.95% (below 0%: shrinking) −38.89% (below 0%: shrinking) +1,378.70% (above 0%: growing) 70.90% 6.54%
NNNN Anbio Biotechnology $516.6M — — — — — — — Compare
ANGO AngioDynamics, Inc. $496.7M — (loss-making) — (loss-making) +6.87% (above 0%: growing) n/m +5.62% (above 0%: growing) 59.37% (9.02%) Compare
Median of peers $1.8B 199× 118× +11.34% — −17.95% 56.50% 1.45%

All 53 Medical Instruments & Supplies stocks →

STAAR Surgical Company (STAA) Latest News

5 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · GuruFocus.com
Impact 3 · · MarketBeat

4 Nov

Impact 3 · · StockStory
Impact 3 · · Business Wire

29 Oct

Impact 4 · · Business Wire

28 Oct

Impact 3 · · Zacks

27 Oct

Impact 3 · · Business Wire

21 Oct

Impact 3 · · Business Wire

14 Oct

Impact 3 · · Simply Wall St.

13 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

12 Oct

Impact 3 · · StockStory

8 Oct

Impact 4 · · Business Wire

29 Sep

Impact 4 · · The Motley Fool
Impact 4 · · StockStory
Impact 4 · · Investing.com

26 Sep

Impact 3 · · StockStory

25 Sep

Impact 3 · · The Motley Fool

24 Sep

Impact 3 · · Investing.com
Impact 3 · · Business Wire

14 Sep

Impact 4 ·
Impact 4 ·
Impact 4 ·

11 Sep

Impact 3 · · medtechdive.com

10 Sep

Impact 4 ·

8 Sep

Impact 3 ·

2 Sep

Impact 3 ·

19 Aug

Impact 4 · · The Motley Fool transcript
stockrow.com/STAA · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com